Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

Summary CP-4126 is a gemcitabine (2′,2′-difluorodeoxycytidine; dFdC) 5′ elaidic acid ester. The purpose of this dose-escalating study was to assess safety, pharmacokinetics (PK) and preliminary antitumor activity of the oral formulation and to determine the recommended dose (RD) for phase II studies...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2013-08, Vol.31 (4), p.959-966
Hauptverfasser:	Stuurman, F. E., Voest, E. E., Awada, A., Witteveen, P. O., Bergeland, T., Hals, P.-A., Rasch, W., Schellens, J. H. M., Hendlisz, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Biological and medical sciences Bone marrow Cancer therapies Chemotherapy Demography Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacokinetics Deoxycytidine - therapeutic use Drug dosages Drug therapy Fatty acids Female General aspects Humans Kinases Liver Male Medical sciences Medicine Medicine & Public Health Metabolism Metabolites Metastasis Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Staging Neoplasms - drug therapy Neoplasms - pathology Oncology Oral administration Patients Pharmaceutical sciences Pharmacokinetics Pharmacology. Drug treatments Pharmacology/Toxicology Phase I Studies Ribonucleotide reductase Studies Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!